Neuroone Medical Technologies (NMTC) Debt to Equity (2010 - 2024)

Neuroone Medical Technologies (NMTC) reported Debt to Equity of $0.03 for Q1 2024, up 53.07% sequentially from $0.02 in Q3 2023.

Neuroone Medical Technologies (NMTC) Debt to Equity (2010 - 2024) Analysis & Trends

Neuroone Medical Technologies has disclosed Debt to Equity across 9 years of filings, most recently posting $0.03 for Q1 2024.

Quarterly Debt to Equity changed N/A year-over-year to $0.03 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $0.03 (changed N/A YoY) and the FY2023 annual result came in at $0.02, changed N/A from the prior year.
Debt to Equity climbed to $0.03 in Q1 2024, from $0.02 in the prior quarter.
Across five years, Debt to Equity topped out at $0.03 in Q1 2024 and bottomed at $0.02 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	0.65
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.64
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.57
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	0.42
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	0.06
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.71
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.95
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	0.27
10	Neuroone Medical Technologies	26.73 Mn	23.93 Mn	990,264.00	-

Download Data